Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PCVX Stock Forecast 2025-2026
$46.48
Current Price
$6.08B
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PCVX Price Targets
+214.1%
To High Target of $146.00
+88.3%
To Median Target of $87.50
-18.2%
To Low Target of $38.00
PCVX Price Momentum
-6.3%
1 Week Change
+11.6%
1 Month Change
-50.2%
1 Year Change
-43.2%
Year-to-Date Change
-50.9%
From 52W High of $94.60
+68.0%
From 52W Low of $27.66
📊 TOP ANALYST CALLS
Did PCVX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vaxcyte is one of their latest high-conviction picks.
Latest PCVX Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, PCVX has a bullish consensus with a median price target of $87.50 (ranging from $38.00 to $146.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $46.48, the median forecast implies a 88.3% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Asad Haider at Goldman Sachs, suggesting a 18.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PCVX Analyst Ratings
8
Buy
1
Hold
0
Sell
PCVX Price Target Range
Low
$38.00
Average
$87.50
High
$146.00
Current: $46.48
Latest PCVX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PCVX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $85.00 |
| Sep 12, 2025 | Goldman Sachs | Asad Haider | Neutral | Initiates | $38.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Initiates | $N/A |
| Apr 8, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $90.00 |
| Apr 1, 2025 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $100.00 |
| Apr 1, 2025 | B of A Securities | Jason Gerberry | Buy | Maintains | $137.00 |
| Apr 1, 2025 | Needham | Joseph Stringer | Buy | Maintains | $90.00 |
| Mar 12, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $160.00 |
| Feb 26, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $140.00 |
| Feb 26, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $160.00 |
| Feb 24, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Feb 11, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $14.00 |
| Dec 24, 2024 | BTIG | Buy | Reiterates | $N/A | |
| Dec 20, 2024 | Goldman Sachs | Chris Shibutani | Buy | Initiates | $135.00 |
| Nov 6, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Nov 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $140.00 |
| Sep 10, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $163.00 |
| Sep 4, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $140.00 |
| Sep 3, 2024 | BTIG | Thomas Shrader | Buy | Maintains | $160.00 |
| Sep 3, 2024 | Needham | Joseph Stringer | Buy | Maintains | $140.00 |
Vaxcyte, Inc. (PCVX) Competitors
The following stocks are similar to Vaxcyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vaxcyte, Inc. (PCVX) Financial Data
Vaxcyte, Inc. has a market capitalization of $6.08B with a P/E ratio of -12.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -20.8%.
Valuation Metrics
Market Cap
$6.08B
Enterprise Value
$4.40B
P/E Ratio
-12.2x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+28.1%
Current Ratio
8.8x
Debt/Equity
2.9x
ROE
-20.8%
ROA
-15.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vaxcyte, Inc. (PCVX) Business Model
About Vaxcyte, Inc.
What They Do
Develops innovative vaccines for infectious diseases.
Business Model
Vaxcyte Inc. utilizes a proprietary cell-free protein synthesis platform to create safer and more effective vaccines. The company focuses on addressing infectious diseases with high unmet medical needs, generating revenue through the development and eventual commercialization of its vaccine candidates in the pharmaceutical market.
Additional Information
Vaxcyte plays a crucial role in advancing preventative healthcare, targeting significant global health challenges. Its innovative approach has the potential to redefine vaccine development standards and improve public health outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
414
CEO
Mr. Grant E. Pickering M.B.A.
Country
United States
IPO Year
2020
Website
vaxcyte.comVaxcyte, Inc. (PCVX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
Dec 02, 2025
By Sundeep Ganoria
Analyst Blog
Latest News
Quick Summary
Final data from the VAX-24 Phase 2 study in infants align with positive interim results, supporting the evaluation of higher doses in the ongoing VAX-31 Phase 2 study.
Why It Matters
Positive data from the VAX-24 study reinforces confidence in the vaccine's effectiveness, potentially boosting the company's stock and future investment prospects in pediatric healthcare.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vaxcyte has signed a new agreement with Thermo Fisher Scientific to enhance domestic production capacity for its broad-spectrum pneumococcal conjugate vaccine candidates.
Why It Matters
The agreement enhances Vaxcyte's manufacturing capabilities, potentially accelerating vaccine production and revenue growth, positively influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vaxcyte, Inc. (NASDAQ: PCVX) will present at the Cantor Global Healthcare Conference on September 3, 2025, at 2:45 PM EDT, featuring key executives.
Why It Matters
Vaxcyte's participation in a major healthcare conference signals potential updates on its pipeline or strategy, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
3 months ago
Quick Summary
VAX-31 Optimized Dose aims to enhance immune responses in infants against Invasive Pneumococcal Disease, utilizing 4.4mcg for most serotypes and 3.3mcg for the remainder.
Why It Matters
VAX-31's optimized dosing may enhance immune responses in infants, potentially leading to increased market demand and revenue for the developing company, impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Vaxcyte (PCVX) Q2 Loss Widens 11%
4 months ago
Quick Summary
Vaxcyte (PCVX) reported an 11% increase in its Q2 loss, indicating worsening financial performance compared to the previous quarter.
Why It Matters
A widening loss for Vaxcyte indicates increasing financial strain, potentially affecting stock performance and investor confidence in the company's future profitability.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Vaxcyte, Inc. is finalizing a Phase 3 program for VAX-31, a potential PCV, with a pivotal study expected to start in Q4 2025. The company reported $2.8 billion in cash as of June 30, 2025.
Why It Matters
The progress on VAX-31's Phase 3 clinical program and strong cash position signal potential growth and innovation in the vaccine market, which could lead to increased investor interest and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PCVX Stock
What is Vaxcyte, Inc.'s (PCVX) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Vaxcyte, Inc. (PCVX) has a median price target of $87.50. The highest price target is $146.00 and the lowest is $38.00.
Is PCVX stock a good investment in 2026?
According to current analyst ratings, PCVX has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $46.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PCVX stock?
Wall Street analysts predict PCVX stock could reach $87.50 in the next 12 months. This represents a 88.3% increase from the current price of $46.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vaxcyte, Inc.'s business model?
Vaxcyte Inc. utilizes a proprietary cell-free protein synthesis platform to create safer and more effective vaccines. The company focuses on addressing infectious diseases with high unmet medical needs, generating revenue through the development and eventual commercialization of its vaccine candidates in the pharmaceutical market.
What is the highest forecasted price for PCVX Vaxcyte, Inc.?
The highest price target for PCVX is $146.00 from at , which represents a 214.1% increase from the current price of $46.48.
What is the lowest forecasted price for PCVX Vaxcyte, Inc.?
The lowest price target for PCVX is $38.00 from Asad Haider at Goldman Sachs, which represents a -18.2% decrease from the current price of $46.48.
What is the overall PCVX consensus from analysts for Vaxcyte, Inc.?
The overall analyst consensus for PCVX is bullish. Out of 14 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $87.50.
How accurate are PCVX stock price projections?
Stock price projections, including those for Vaxcyte, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 7:02 PM UTC